200 related articles for article (PubMed ID: 35433442)
1.
Mohajershojai T; Jha P; Boström A; Frejd FY; Yazaki PJ; Nestor M
Front Oncol; 2022; 12():849338. PubMed ID: 35433442
[TBL] [Abstract][Full Text] [Related]
2. Enhanced Therapeutic Effects of
Mohajershojai T; Spangler D; Chopra S; Frejd FY; Yazaki PJ; Nestor M
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686514
[TBL] [Abstract][Full Text] [Related]
3. Phase I Study of Yttrium-90 Radiolabeled M5A Anti-Carcinoembryonic Antigen Humanized Antibody in Patients with Advanced Carcinoembryonic Antigen Producing Malignancies.
Akhavan D; Yazaki P; Yamauchi D; Simpson J; Frankel PH; Bading J; Colcher D; Poku K; Chen YJ; Lim D; Cristea M; Wu A; Shively J; Wong JYC
Cancer Biother Radiopharm; 2020 Feb; 35(1):10-15. PubMed ID: 31910346
[No Abstract] [Full Text] [Related]
4. First-In-Human Pilot PET Immunoimaging Study of
Wong JYC; Yamauchi DM; Adhikarla V; Simpson J; Frankel PH; Fong Y; Melstrom KA; Chen YJ; Salehian BD; Woo Y; Dandapani SV; Colcher DM; Poku EK; Yazaki PJ; Wu AM; Shively JE
Cancer Biother Radiopharm; 2023 Feb; 38(1):26-37. PubMed ID: 36154291
[No Abstract] [Full Text] [Related]
5. Enhancing the therapeutic effects of in vitro targeted radionuclide therapy of 3D multicellular tumor spheroids using the novel stapled MDM2/X-p53 antagonist PM2.
Mortensen ACL; Morin E; Brown CJ; Lane DP; Nestor M
EJNMMI Res; 2020 Apr; 10(1):38. PubMed ID: 32300907
[TBL] [Abstract][Full Text] [Related]
6. Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma.
Zhang C; Wang L; Zhang Q; Shen J; Huang X; Wang M; Huang Y; Chen J; Xu Y; Zhao W; Qi Y; Li Y; Ou Y; Yang Z; Qian C
Front Immunol; 2023; 14():1182409. PubMed ID: 37304295
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunoimaging of liver metastases with PET using a 64Cu-labeled CEA antibody in transgenic mice.
Nittka S; Krueger MA; Shively JE; Boll H; Brockmann MA; Doyon F; Pichler BJ; Neumaier M
PLoS One; 2014; 9(9):e106921. PubMed ID: 25226518
[TBL] [Abstract][Full Text] [Related]
8. The HSP90 inhibitor onalespib potentiates 177Lu‑DOTATATE therapy in neuroendocrine tumor cells.
Lundsten S; Spiegelberg D; Stenerlöw B; Nestor M
Int J Oncol; 2019 Dec; 55(6):1287-1295. PubMed ID: 31638190
[TBL] [Abstract][Full Text] [Related]
9. The radiosensitizer Onalespib increases complete remission in
Lundsten S; Spiegelberg D; Raval NR; Nestor M
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):980-990. PubMed ID: 31912256
[TBL] [Abstract][Full Text] [Related]
10. PEGylated Fluorescent Anti-carcinoembryonic Antigen Antibody Labels Colorectal Cancer Tumors in Orthotopic Mouse Models.
Turner MA; Amirfakhri S; Nishino H; Neel NC; Hosseini M; Cox KE; Lwin TM; Li L; Hong T; Sherman A; Shively JE; Hoffman RM; Yazaki PJ; Bouvet M
J Surg Res; 2023 Nov; 291():596-602. PubMed ID: 37540977
[TBL] [Abstract][Full Text] [Related]
11. Humanization of the anti-CEA T84.66 antibody based on crystal structure data.
Yazaki PJ; Sherman MA; Shively JE; Ikle D; Williams LE; Wong JY; Colcher D; Wu AM; Raubitschek AA
Protein Eng Des Sel; 2004 May; 17(5):481-9. PubMed ID: 15316127
[TBL] [Abstract][Full Text] [Related]
12. Clinical Dose Preparation of [
Menon SR; Mitra A; Chakraborty A; Tawate M; Sahu S; Rakshit S; Gaikwad S; Dhotre G; Damle A; Banerjee S
Cancer Biother Radiopharm; 2022 Jun; 37(5):384-402. PubMed ID: 35575711
[No Abstract] [Full Text] [Related]
13. A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance.
Yazaki PJ; Lee B; Channappa D; Cheung CW; Crow D; Chea J; Poku E; Li L; Andersen JT; Sandlie I; Orcutt KD; Wittrup KD; Shively JE; Raubitschek A; Colcher D
Protein Eng Des Sel; 2013 Mar; 26(3):187-93. PubMed ID: 23175797
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
[TBL] [Abstract][Full Text] [Related]
15. α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.
Heskamp S; Hernandez R; Molkenboer-Kuenen JDM; Essler M; Bruchertseifer F; Morgenstern A; Steenbergen EJ; Cai W; Seidl C; McBride WJ; Goldenberg DM; Boerman OC
J Nucl Med; 2017 Jun; 58(6):926-933. PubMed ID: 28232604
[TBL] [Abstract][Full Text] [Related]
16. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
17. AAZTA
Klasen B; Moon ES; Rösch F
Nucl Med Biol; 2021; 96-97():80-93. PubMed ID: 33839678
[TBL] [Abstract][Full Text] [Related]
18. Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma.
Lindenblatt D; Terraneo N; Pellegrini G; Cohrs S; Spycher PR; Vukovic D; Béhé M; Schibli R; Grünberg J
BMC Cancer; 2018 Sep; 18(1):922. PubMed ID: 30253737
[TBL] [Abstract][Full Text] [Related]
19. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
[TBL] [Abstract][Full Text] [Related]
20. Humanized Anti-Carcinoembryonic Antigen Antibodies Brightly Target and Label Gastric Cancer in Orthotopic Mouse Models.
Cox KE; Turner MA; Amirfakhri S; Lwin TM; Hosseini M; Ghosh P; Obonyo M; Murakami T; Hoffman RM; Yazaki PJ; Bouvet M
J Surg Res; 2024 Jan; 293():701-708. PubMed ID: 37839102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
